Drug Profile

Influenza A virus H1N1 vaccine - Hard To Treat Diseases

Alternative Names: Swine flu vaccine - Hard To Treat Diseases/Mellow Hope/Zhejiang Tianyuan Bio-pharmaceutical

Latest Information Update: 02 Apr 2015

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Hard To Treat Diseases
Class Influenza A virus H1N1 vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Registered Influenza A virus H1N1 subtype

Most Recent Events

22 Mar 2011 Zhejiang Tianyuan Bio-pharmaceutical has been acquired by Novartis
19 Nov 2009 Registered for Influenza-A virus H1N1 subtype in Chile (Parenteral)
29 Sep 2009 Registered for Influenza-A virus H1N1 subtype in China (Parenteral)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com